Carna BiosciencesCarna Biosciences, Inc.4572東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP
It lost about ¥358 for every ¥100 of sales at the operating level. Revenue changed -9.0% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -9.8% | —× | — |
| 2022 | — | —× | -27.8% | —× | — |
| 2023 | — | —× | -26.8% | —× | — |
| 2024 | — | —× | -61.2% | —× | — |
| 2025 | — | —× | -108.5% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2,018 | 1,387 | 1,626 | 636 | 579 |
| Cost of revenue | 135 | 172 | 175 | 171 | 191 |
| Gross profit | 1,882 | 1,215 | 1,451 | 466 | 388 |
| SG&A | 2,413 | 2,485 | 2,568 | 2,542 | 2,463 |
| Operating income | -531 | -1,270 | -1,117 | -2,076 | -2,075 |
| Pretax income | -532 | -1,323 | -1,131 | -2,174 | -2,170 |
| Income tax | 2 | 26 | 22 | 5 | 2 |
| Net income attributable to owners | -534 | -1,350 | -1,153 | -2,179 | -2,171 |
| Operating margin | -26.3% | -91.6% | -68.7% | -326.3% | -358.3% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.82B | ¥3.38B | ¥2.89B | ¥2.11B | ¥516.8M |
| Total assets | ¥5.43B | ¥4.27B | ¥4.35B | ¥2.77B | ¥1.23B |
| Net assets | ¥4.32B | ¥3.64B | ¥3.88B | ¥2.48B | ¥309.2M |
| Share capital | ¥1.06B | ¥1.38B | ¥2.08B | ¥2.45B | ¥14.8M |
| Property, plant and equipment | ¥51.6M | ¥100.2M | ¥105.5M | — | — |
| Intangible assets excluding goodwill | ¥2.7M | ¥1.9M | ¥1.1M | — | — |
| Investment securities | — | — | — | ¥11.4M | ¥28.5M |
| Current assets | ¥5.32B | ¥4.1B | ¥4.19B | ¥2.74B | ¥1.18B |
| Current liabilities | ¥774.7M | ¥436.4M | ¥375.9M | ¥223M | ¥168.1M |
| Long-term borrowings | ¥268.4M | ¥148.4M | ¥28.4M | ¥8.4M | — |
| Bonds | ¥32M | — | — | — | — |
| Total liabilities | ¥1.12B | ¥624.6M | ¥472.4M | ¥296.8M | ¥920.4M |
| Equity attributable to owners of parent | ¥4.29B | ¥3.59B | ¥3.83B | ¥2.39B | ¥230.7M |
| Retained earnings | -¥1.57B | -¥2.92B | -¥4.08B | -¥6.25B | -¥1.98B |
| Treasury stock | -¥222K | -¥222K | -¥222K | -¥222K | -¥227K |
EDINET (FSA Japan)
有価証券報告書－第23期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.